A Phase 1/2 Study of Ramucirumab Plus Nivolumab in Participants With Gastric or GEJ Cancer

NCT02999295 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

46

Enrollment

OTHER_GOV

Sponsor class

Conditions

Gastric Cancer
Gastroesophageal Junction Region (GEJ) Cancer

Interventions

BIOLOGICAL: Ramucirumab
BIOLOGICAL: Nivolumab

Sponsor

National Cancer Center, Japan

Collaborators

[object Object]
[object Object]